GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

Yazhou Li, TracyAnn Perry, Mark S. Kindy, Brandon K. Harvey, David Tweedie, Harold W. Holloway, Kathleen Powers, Hui Shen, Josephine M. Egan, Kumar Sambamurti, Arnold Brossi, Debomoy Lahiri, Mark P. Mattson, Barry J. Hoffer, Yun Wang, Nigel H. Greig

Research output: Contribution to journalArticle

298 Citations (Scopus)

Abstract

Glucagon-like peptide-1 (GLP-1) is an endogenous insulinotropic peptide secreted from the gastrointestinal tract in response to food intake. It enhances pancreatic islet β-cell proliferation and glucose-dependent insulin secretion, and lowers blood glucose and food intake in patients with type 2 diabetes mellitus (T2DM). A long-acting GLP-1 receptor (GLP-1R) agonist, exendin-4 (Ex-4), is the first of this new class of antihyperglycemia drugs approved to treat T2DM. GLP-1Rs are coupled to the cAMP second messenger pathway and, along with pancreatic cells, are expressed within the nervous system of rodents and humans, where receptor activation elicits neurotrophic actions. We detected GLP-1R mRNA expression in both cultured embryonic primary cerebral cortical and ventral mesencephalic (dopaminergic) neurons. These cells are vulnerable to hypoxia- and 6-hydroxydopamine-induced cell death, respectively. We found that GLP-1 and Ex-4 conferred protection in these cells, but not in cells from Glp1r knockout (-/-) mice. Administration of Ex-4 reduced brain damage and improved functional outcome in a transient middle cerebral artery occlusion stroke model. Ex-4 treatment also protected dopaminergic neurons against degeneration, preserved dopamine levels, and improved motor function in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease (PD). Our findings demonstrate that Ex-4 can protect neurons against metabolic and oxidative insults, and they provide preclinical support for the therapeutic potential for Ex-4 in the treatment of stroke and PD.

Original languageEnglish
Pages (from-to)1285-1290
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume106
Issue number4
DOIs
StatePublished - Jan 27 2009

Fingerprint

Dopaminergic Neurons
Parkinsonian Disorders
Rodentia
Stroke
Glucagon-Like Peptide 1
Middle Cerebral Artery Infarction
Islets of Langerhans
Type 2 Diabetes Mellitus
Parkinson Disease
Eating
Nerve Degeneration
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Cytoprotection
Oxidopamine
Second Messenger Systems
Knockout Mice
Nervous System
Blood Glucose
Gastrointestinal Tract
Glucagon-Like Peptide-1 Receptor

Keywords

  • Diabetes
  • Exendin-4
  • Neurodegeneration
  • Neuroprotection
  • Stroke

ASJC Scopus subject areas

  • General

Cite this

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. / Li, Yazhou; Perry, TracyAnn; Kindy, Mark S.; Harvey, Brandon K.; Tweedie, David; Holloway, Harold W.; Powers, Kathleen; Shen, Hui; Egan, Josephine M.; Sambamurti, Kumar; Brossi, Arnold; Lahiri, Debomoy; Mattson, Mark P.; Hoffer, Barry J.; Wang, Yun; Greig, Nigel H.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 106, No. 4, 27.01.2009, p. 1285-1290.

Research output: Contribution to journalArticle

Li, Y, Perry, T, Kindy, MS, Harvey, BK, Tweedie, D, Holloway, HW, Powers, K, Shen, H, Egan, JM, Sambamurti, K, Brossi, A, Lahiri, D, Mattson, MP, Hoffer, BJ, Wang, Y & Greig, NH 2009, 'GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism', Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 4, pp. 1285-1290. https://doi.org/10.1073/pnas.0806720106
Li, Yazhou ; Perry, TracyAnn ; Kindy, Mark S. ; Harvey, Brandon K. ; Tweedie, David ; Holloway, Harold W. ; Powers, Kathleen ; Shen, Hui ; Egan, Josephine M. ; Sambamurti, Kumar ; Brossi, Arnold ; Lahiri, Debomoy ; Mattson, Mark P. ; Hoffer, Barry J. ; Wang, Yun ; Greig, Nigel H. / GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. In: Proceedings of the National Academy of Sciences of the United States of America. 2009 ; Vol. 106, No. 4. pp. 1285-1290.
@article{8a797cd05dc440cb87094d03fc84be38,
title = "GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism",
abstract = "Glucagon-like peptide-1 (GLP-1) is an endogenous insulinotropic peptide secreted from the gastrointestinal tract in response to food intake. It enhances pancreatic islet β-cell proliferation and glucose-dependent insulin secretion, and lowers blood glucose and food intake in patients with type 2 diabetes mellitus (T2DM). A long-acting GLP-1 receptor (GLP-1R) agonist, exendin-4 (Ex-4), is the first of this new class of antihyperglycemia drugs approved to treat T2DM. GLP-1Rs are coupled to the cAMP second messenger pathway and, along with pancreatic cells, are expressed within the nervous system of rodents and humans, where receptor activation elicits neurotrophic actions. We detected GLP-1R mRNA expression in both cultured embryonic primary cerebral cortical and ventral mesencephalic (dopaminergic) neurons. These cells are vulnerable to hypoxia- and 6-hydroxydopamine-induced cell death, respectively. We found that GLP-1 and Ex-4 conferred protection in these cells, but not in cells from Glp1r knockout (-/-) mice. Administration of Ex-4 reduced brain damage and improved functional outcome in a transient middle cerebral artery occlusion stroke model. Ex-4 treatment also protected dopaminergic neurons against degeneration, preserved dopamine levels, and improved motor function in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease (PD). Our findings demonstrate that Ex-4 can protect neurons against metabolic and oxidative insults, and they provide preclinical support for the therapeutic potential for Ex-4 in the treatment of stroke and PD.",
keywords = "Diabetes, Exendin-4, Neurodegeneration, Neuroprotection, Stroke",
author = "Yazhou Li and TracyAnn Perry and Kindy, {Mark S.} and Harvey, {Brandon K.} and David Tweedie and Holloway, {Harold W.} and Kathleen Powers and Hui Shen and Egan, {Josephine M.} and Kumar Sambamurti and Arnold Brossi and Debomoy Lahiri and Mattson, {Mark P.} and Hoffer, {Barry J.} and Yun Wang and Greig, {Nigel H.}",
year = "2009",
month = "1",
day = "27",
doi = "10.1073/pnas.0806720106",
language = "English",
volume = "106",
pages = "1285--1290",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "4",

}

TY - JOUR

T1 - GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

AU - Li, Yazhou

AU - Perry, TracyAnn

AU - Kindy, Mark S.

AU - Harvey, Brandon K.

AU - Tweedie, David

AU - Holloway, Harold W.

AU - Powers, Kathleen

AU - Shen, Hui

AU - Egan, Josephine M.

AU - Sambamurti, Kumar

AU - Brossi, Arnold

AU - Lahiri, Debomoy

AU - Mattson, Mark P.

AU - Hoffer, Barry J.

AU - Wang, Yun

AU - Greig, Nigel H.

PY - 2009/1/27

Y1 - 2009/1/27

N2 - Glucagon-like peptide-1 (GLP-1) is an endogenous insulinotropic peptide secreted from the gastrointestinal tract in response to food intake. It enhances pancreatic islet β-cell proliferation and glucose-dependent insulin secretion, and lowers blood glucose and food intake in patients with type 2 diabetes mellitus (T2DM). A long-acting GLP-1 receptor (GLP-1R) agonist, exendin-4 (Ex-4), is the first of this new class of antihyperglycemia drugs approved to treat T2DM. GLP-1Rs are coupled to the cAMP second messenger pathway and, along with pancreatic cells, are expressed within the nervous system of rodents and humans, where receptor activation elicits neurotrophic actions. We detected GLP-1R mRNA expression in both cultured embryonic primary cerebral cortical and ventral mesencephalic (dopaminergic) neurons. These cells are vulnerable to hypoxia- and 6-hydroxydopamine-induced cell death, respectively. We found that GLP-1 and Ex-4 conferred protection in these cells, but not in cells from Glp1r knockout (-/-) mice. Administration of Ex-4 reduced brain damage and improved functional outcome in a transient middle cerebral artery occlusion stroke model. Ex-4 treatment also protected dopaminergic neurons against degeneration, preserved dopamine levels, and improved motor function in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease (PD). Our findings demonstrate that Ex-4 can protect neurons against metabolic and oxidative insults, and they provide preclinical support for the therapeutic potential for Ex-4 in the treatment of stroke and PD.

AB - Glucagon-like peptide-1 (GLP-1) is an endogenous insulinotropic peptide secreted from the gastrointestinal tract in response to food intake. It enhances pancreatic islet β-cell proliferation and glucose-dependent insulin secretion, and lowers blood glucose and food intake in patients with type 2 diabetes mellitus (T2DM). A long-acting GLP-1 receptor (GLP-1R) agonist, exendin-4 (Ex-4), is the first of this new class of antihyperglycemia drugs approved to treat T2DM. GLP-1Rs are coupled to the cAMP second messenger pathway and, along with pancreatic cells, are expressed within the nervous system of rodents and humans, where receptor activation elicits neurotrophic actions. We detected GLP-1R mRNA expression in both cultured embryonic primary cerebral cortical and ventral mesencephalic (dopaminergic) neurons. These cells are vulnerable to hypoxia- and 6-hydroxydopamine-induced cell death, respectively. We found that GLP-1 and Ex-4 conferred protection in these cells, but not in cells from Glp1r knockout (-/-) mice. Administration of Ex-4 reduced brain damage and improved functional outcome in a transient middle cerebral artery occlusion stroke model. Ex-4 treatment also protected dopaminergic neurons against degeneration, preserved dopamine levels, and improved motor function in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease (PD). Our findings demonstrate that Ex-4 can protect neurons against metabolic and oxidative insults, and they provide preclinical support for the therapeutic potential for Ex-4 in the treatment of stroke and PD.

KW - Diabetes

KW - Exendin-4

KW - Neurodegeneration

KW - Neuroprotection

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=59049087723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59049087723&partnerID=8YFLogxK

U2 - 10.1073/pnas.0806720106

DO - 10.1073/pnas.0806720106

M3 - Article

VL - 106

SP - 1285

EP - 1290

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 4

ER -